Carbogen Amcis to buy GEA plant and convert it for API production

By Gareth Macdonald

- Last updated on GMT

Carbogen Amcis to buy GEA plant in Bubendorf (source Google)
Carbogen Amcis to buy GEA plant in Bubendorf (source Google)

Related tags Pharmacology

Carbogen Amcis plans to buy a GEA Pharma Systems facility in Bubendorf, Switzerland to support its API and ADC businesses. 

The facility – ownership of which will transfer to Carbogen in January – will make active pharmaceutical ingredients (APIs) under good manufacturing practices (GMP) compliant condition according to the Swiss firm, which expects production to begin in 2017.

The GEA plant is 300 meters from an existing production facility at which Carbogen provides process optimization services and makes drug actives for late-phase clinical trials, commercial supply.

Spokeswoman Lucie Framinet told us the acquisition was prompted by increasing demand from customers.

This acquisition has been mainly made to support our business growth and company expansion as well as to face significant and continuous increase in customers’ demand for additional capacity.

ADC expansion

The GEA facility will also “support our ADC capacity from early phase up to commercial scale​” according to Framinet

Carbogen has made a number of investments in its antibody drug conjugate (ADC) production offering in the past few years.

In 2013​ it partnered with St Asaph, Wales based specialist ADC Biotechnology and set up dedicated clean room capacity at the Bubendorf site and another facility in Riom, France.

More recently​ Carbogen signed a long-term lease agreement with chemicals and biotechnology firm Bachem to take over a high-containment unit it owns in Vionnaz, Switzerland.

Although the project conducted with ADC Biotechnology is now completed the "Vionnaz is growing and is currently undergoing several expansion projects​" Framinet said.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...